Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DTYMK | P23919 | 2/20 | 0.73 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17782897 | 0.92 | DTYMK (0.73) | DTYMK | |
| SCHEMBL9886464 | 0.84 | DTYMK (1.00) | DTYMKCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL17782898 | 0.83 | DTYMK (0.76) | DTYMKCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL17790406 | 0.82 | DTYMK (0.74) | DTYMKCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL17782903 | 0.81 | DTYMK (0.70) | DTYMKCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL17782862 | 0.81 | DTYMK (0.73) | DTYMKCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL17782892 | 0.81 | DTYMK (0.73) | DTYMKCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL17782928 | 0.81 | DTYMK (0.73) | DTYMKCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL17782915 | 0.80 | DTYMK (0.72) | DTYMKCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL17782917 | 0.79 | DTYMK (0.70) | DTYMKCHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662328-B2 | Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells | NATIONAL TAIWAN UNIVERSITY (TW) | 2017-05-30 | — | — | US | disclosed |
| US-9662328-B2 | Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells | NATIONAL TAIWAN UNIVERSITY (TW) | 2017-05-30 | — | — | US | disclosed |
| US-9662328-B2 | Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells | NATIONAL TAIWAN UNIVERSITY (TW) | 2017-05-30 | — | — | US | disclosed |
| US-20160151362-A1 | TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS | NATIONAL TAIWAN UNIVERSITY (TW) | 2016-06-02 | — | — | US | disclosed |
| US-20160151362-A1 | TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS | NATIONAL TAIWAN UNIVERSITY (TW) | 2016-06-02 | — | — | US | disclosed |
| US-20160151362-A1 | TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS | NATIONAL TAIWAN UNIVERSITY (TW) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151362-A1 | TARGETING HUMAN THYMIDYLATE KINASE INDUCES DNA REPAIR TOXICITY IN MALIGNANT TUMOR CELLS | DTYMK, TYMP, TK1 | DTYMK 1/4885PLK1 272/4885CHRM2 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.